TY - JOUR
T1 - Fatigability and endurance performance in cancer survivors
T2 - Analyses from the Baltimore Longitudinal Study of Aging
AU - Gresham, Gillian
AU - Dy, Sydney M.
AU - Zipunnikov, Vadim
AU - Browner, Ilene S.
AU - Studenski, Stephanie A.
AU - Simonsick, Eleanor M.
AU - Ferrucci, Luigi
AU - Schrack, Jennifer A.
N1 - Publisher Copyright:
© 2018 American Cancer Society
PY - 2018/3/15
Y1 - 2018/3/15
N2 - BACKGROUND: Fatigue is prevalent and distressing among cancer survivors, but its subjective nature makes it difficult to identify. Fatigability, defined as task-specific fatigue, and endurance performance may be useful supplemental measures of functional status in cancer survivors. METHODS: Fatigability, endurance performance, and cancer history were assessed every 2 years in Baltimore Longitudinal Study of Aging participants between 2007 and 2015. Fatigability was defined according to the Borg rating of perceived exertion scale after a 5-minute, slow treadmill walk; and endurance performance was calculated according to the ability and time to complete a fast-paced, 400-meter walk. The association between cancer history, fatigability, and endurance performance was evaluated using longitudinal analyses adjusted for age, sex, body mass index, and comorbidities. RESULTS: Of 1665 participants, 334 (20%) reported a history of cancer. A combination of older age (>65 years) and a history of cancer was associated with 3.8 and 8.6 greater odds of high perceived fatigability and poor endurance, respectively (P <.01). Older adults with and without a history of cancer walked 42 and 23 seconds slower than younger adults without a history of cancer, respectively (P <.01). The median times to the development of high fatigability and poor endurance were shorter among those who had a history of cancer compared with those who had no history of cancer (P <.01). CONCLUSIONS: The current findings suggest that a history of cancer is associated with fatigability and poor endurance and that this effect is significantly greater in older adults. Evaluating the effects of cancer and age on fatigability may illuminate potential pathways and targets for future interventions. Cancer 2018;124:1279-87.
AB - BACKGROUND: Fatigue is prevalent and distressing among cancer survivors, but its subjective nature makes it difficult to identify. Fatigability, defined as task-specific fatigue, and endurance performance may be useful supplemental measures of functional status in cancer survivors. METHODS: Fatigability, endurance performance, and cancer history were assessed every 2 years in Baltimore Longitudinal Study of Aging participants between 2007 and 2015. Fatigability was defined according to the Borg rating of perceived exertion scale after a 5-minute, slow treadmill walk; and endurance performance was calculated according to the ability and time to complete a fast-paced, 400-meter walk. The association between cancer history, fatigability, and endurance performance was evaluated using longitudinal analyses adjusted for age, sex, body mass index, and comorbidities. RESULTS: Of 1665 participants, 334 (20%) reported a history of cancer. A combination of older age (>65 years) and a history of cancer was associated with 3.8 and 8.6 greater odds of high perceived fatigability and poor endurance, respectively (P <.01). Older adults with and without a history of cancer walked 42 and 23 seconds slower than younger adults without a history of cancer, respectively (P <.01). The median times to the development of high fatigability and poor endurance were shorter among those who had a history of cancer compared with those who had no history of cancer (P <.01). CONCLUSIONS: The current findings suggest that a history of cancer is associated with fatigability and poor endurance and that this effect is significantly greater in older adults. Evaluating the effects of cancer and age on fatigability may illuminate potential pathways and targets for future interventions. Cancer 2018;124:1279-87.
KW - aging
KW - cancer-related fatigue
KW - fatigability
KW - functionality
KW - mobility
KW - survivorship
UR - http://www.scopus.com/inward/record.url?scp=85041695806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041695806&partnerID=8YFLogxK
U2 - 10.1002/cncr.31238
DO - 10.1002/cncr.31238
M3 - Article
C2 - 29419879
AN - SCOPUS:85041695806
SN - 0008-543X
VL - 124
SP - 1279
EP - 1287
JO - Cancer
JF - Cancer
IS - 6
ER -